HCPCS Code Applications and Approvals: October 2023
Quarterly archive · CMS Level II HCPCS19 coding decisions from the Second Quarter 2023 CMS cycle
These are the Centers for Medicare and Medicaid Services (CMS) Level II HCPCS drug coding decisions from the Second Quarter 2023 coding cycle, which took effect October 1, 2023.
For the newest decisions, see the current HCPCS code applications and approvals.
CMS Level II HCPCS Drug Coding Decisions
Does not include Q4 skin repair and wound codes.
How to Read This Table
- Action
- CMS decision on the application — establish a new code, revise an existing descriptor, reinstate a code, or discontinue one. See the glossary.
- Code Change
- Where CMS retires a code in favor of another, the new code shows the code it replaces and the retired code shows its replacement.
- 505(b)(2) and Biosimilar
- Tags beside the drug name mark products approved under the FDA 505(b)(2) pathway and biosimilars.
- Effective
- First date of service on which the code may be billed. Codes effective before this quarter reflect retroactive establishment; codes effective after it are decisions CMS scheduled for a later quarter.
October 2023
| HCPCS | Drug & Descriptor | Company | Code Change | Action | Effective |
|---|---|---|---|---|---|
| A9573 | Elucirem Injection, gadopiclenol, 1 ml | Guerbet LLC | — | Establish | |
| A9603 | CYTALUX Injection, pafolacianine, 0.1 mg | Hull Associates Intravenous | — | Establish | |
| A9697 | Magtrace Injection, carboxydextran-coated superparamagnetic iron oxide, per study dose | Endomag Subcutaneous | — | Establish | |
| J0174 | LEQEMBI Injection, lecanemab-irmb, 1 mg | Eisai Intravenous | — | Establish | |
| J0349 | REZZAYO Injection, rezafungin, 1 mg | Melinta Therapeutics Intravenous | — | Establish | |
| J0801 | ACTHAR GEL Injection, corticotropin (acthar gel), up to 40 units | Mallinckrodt Intramuscular/Subcutaneous | — | Establish | |
| J0802 | ACTHAR GEL Injection, corticotropin (ani), up to 40 units | Mallinckrodt Intramuscular/Subcutaneous | — | Establish | |
| J0874 | Daptomycin in Sodium Chloride Injection 505(b)(2) Injection, daptomycin (baxter), not therapeutically equivalent to j0878, 1 mg | — Intravenous | — | Establish | |
| J0889 | JESDUVROQ Daprodustat, oral, 1 mg, (for esrd on dialysis) | GlaxoSmithKline (GSK) Oral | — | Establish | |
| J2359 | Olanzapine 505(b)(2) Injection, olanzapine, 0.5 mg | — | — | Establish | |
| J2781 | SYFOVRE Injection, pegcetacoplan, intravitreal, 1 mg | Apellis Pharmaceuticals, Inc. Intravitreal | — | Establish | |
| J7214 | ALTUVIIIO Injection, factor viii/von willebrand factor complex, recombinant (altuviiio), per factor viii i.u | Sanofi Intravenous | — | Establish | |
| J7353 | NEXOBRID Anacaulase-bcdb, 8.8% gel, 1 gram | Vericel Corporation Topical | — | Establish | |
| J7519 | Mycophenolate Mofetil Injection, mycophenolate mofetil, 10 mg | — | — | Establish | |
| J9051 | Bortezomib Injection 505(b)(2) Injection, bortezomib (maia), not therapeutically equivalent to j9041, 0.1 mg | MAIA Intravenous | — | Establish | |
| J9064 | Cabazitaxel Injection 505(b)(2) Injection, cabazitaxel (sandoz), not therapeutically equivalent to j9043, 1 mg | Sandoz Inc. (Sandoz) Intravenous | — | Establish | |
| J9345 | ZYNYZ Injection, retifanlimab-dlwr, 1 mg | Incyte Intravenous | — | Establish | |
| Q4285 | NuDYN DL Nudyn dl or nudyn dl mesh, per square centimeter | Fidia Pharma USA Inc. | — | Establish | |
| Q4286 | NuDYN SL Nudyn sl or nudyn slw, per square centimeter | Fidia Pharma USA Inc. | — | Establish |
No coding decisions match those filters.
Source: CMS HCPCS application summaries, Second Quarter 2023 coding cycle (PDF) . Data current as of October 7, 2026.
Other Quarters
Decisions per quarter since July 2022 · select a bar to open that quarter
